Immunogenicity assessment of Ovaleap (R) (XM17) recombinant human follicle-stimulating hormone in infertile women undergoing assisted reproductive technology (ART)

被引：0
|
作者：
Zou, L. [1 ]
Mueller, A. [2 ]
Gertz, B. [2 ]
Weiss, H. [3 ]
Liu, P. [1 ]
机构：
[1] Teva Pharmaceut, Global Bioassays & Technol, W Chester, PA USA
[2] Merckle GmbH, Teva Grp, Ulm, Germany
[3] Teva Global Med Affairs, Petah Tiqwa, Israel
来源：
GIORNALE ITALIANO DI OSTETRICIA E GINECOLOGIA | 2016年 / 38卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：233 / 233
页数：1
相关论文
共 50 条
  • [1] Immunogenicity assessment of Ovaleap® (XM17) recombinant human follicle-stimulating hormone in infertile women undergoing assisted reproductive technology (ART)
    Zou, Linglong
    Mueller, Arnd
    Gertz, Beate
    Weiss, Herman
    Liu, Patrick
    [J]. GYNECOLOGICAL ENDOCRINOLOGY, 2016, 32 : 147 - 147
  • [2] Manufacturing of recombinant human follicle-stimulating hormone Ovaleap (R) (XM17): comparability to Gonal-f (R), formulation, and stability
    Weiss, H.
    Winstel, R.
    Allgaier, H.
    Wieland, J.
    Mueller, A.
    [J]. GIORNALE ITALIANO DI OSTETRICIA E GINECOLOGIA, 2016, 38 (01): : 226 - 226
  • [3] Manufacturing of recombinant human follicle-stimulating hormone Ovaleap® (XM17): comparability to Gonal-f®, formulation, and stability
    Weiss, Herman
    Winstel, Rainer
    Allgaier, Hermann
    Wieland, Juergen
    Mueller, Arnd
    [J]. GYNECOLOGICAL ENDOCRINOLOGY, 2016, 32 : 146 - 147
  • [4] Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap® (XM17), Comparability with Gonal-f®, and Performance/Consistency
    Winstel, Rainer
    Wieland, Juergen
    Gertz, Beate
    Mueller, Arnd
    Allgaier, Hermann
    [J]. DRUGS IN R&D, 2017, 17 (02) : 305 - 312
  • [5] Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap® (XM17), Comparability with Gonal-f®, and Performance/Consistency
    Rainer Winstel
    Juergen Wieland
    Beate Gertz
    Arnd Mueller
    Hermann Allgaier
    [J]. Drugs in R&D, 2017, 17 : 305 - 312
  • [6] Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART)
    Thomas Strowitzki
    Waldemar Kuczynski
    Arnd Mueller
    Peter Bias
    [J]. Reproductive Biology and Endocrinology, 14
  • [7] Phase 1 safety, tolerability, and pharmacokinetic study of single ascending doses of XM17 (recombinant human follicle-stimulating hormone) in downregulated healthy women
    Lammerich, Andreas
    Bias, Peter
    Gertz, Beate
    [J]. INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2015, 7 : 707 - 715
  • [8] Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART)
    Strowitzki, Thomas
    Kuczynski, Waldemar
    Mueller, Arnd
    Bias, Peter
    [J]. REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, 2016, 14
  • [9] Economic evaluation of recombinant follicle-stimulating hormone (Puregon®) in infertile women undergoing IVF in the UK
    Sykes, D
    Out, HJ
    van Loon, JL
    [J]. HUMAN REPRODUCTION, 2000, 15 : 8 - 8
  • [10] Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study
    Thomas Strowitzki
    Waldemar Kuczynski
    Arnd Mueller
    Peter Bias
    [J]. Reproductive Biology and Endocrinology, 14
12345